Literature DB >> 15809732

Deletions and altered expression of the RIZ1 tumour suppressor gene in 1p36 in pheochromocytomas and abdominal paragangliomas.

Janos Geli1, Brita Nord, Tony Frisk, Elisabeth Edström Elder, Tomas J Ekström, Tobias Carling, Martin Bäckdahl, Catharina Larsson.   

Abstract

Pheochromocytomas and abdominal paragangliomas are rare catecholamine-producing tumours arising from neural crest-derived chromaffin cells. Frequent deletions of several distinct regions on the short arm of chromosome 1 suggest their involvement in the tumourigenesis process. The RIZ1 tumour suppressor encoded by the RIZ gene in 1p36.21 represents an attractive candidate target for the distal 1p deletions in these tumours. A panel of 18 pheochromocytomas (14 benign, and 4 malignant) and 11 abdominal paragangliomas (4 benign, and 7 malignant) were characterised for somatic deletions and mRNA expression status of RIZ1 using loss of heterozygosity (LOH) analysis and real-time quantitative PCR, respectively. Furthermore, we evaluated the methylation status of the RIZ1 promoter utilising methylation-specific PCR (MSP). Intragenic LOH at the RIZ locus was detected in 10 of 16 informative cases (62%), including 8 of 12 pheochromocytomas (67%) and 2 of 4 paragangliomas (50%). RIZ1 mRNA appeared to be significantly under-expressed in the tumour samples compared to normal adrenal controls (mean 0.6 vs. 1.0, p<0.001). This was not associated with RIZ1 promoter methylation in any of the samples, indicating that promoter hypermethylation is unlikely to be the underlying cause of the frequent expressional silencing. The recurrent inactivation of the tumour suppressor RIZ1 suggests that this event may be a significant contributing factor to tumour development in pheochromocytomas and abdominal paragangliomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809732

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  1p36.32 rearrangements and the role of PI-PLC η2 in nervous tumours.

Authors:  Vincenza Rita Lo Vasco
Journal:  J Neurooncol       Date:  2010-09-29       Impact factor: 4.130

2.  Lack of association between microsatellite instability and benign adrenal tumors.

Authors:  Fares Namour; Ahmet Ayav; Xiaohong Lu; Marc Klein; Miahela Muresan; Laurent Bresler; Denise Tramoy; Jean-Louis Guéant; Laurent Brunaud
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

Review 3.  Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.

Authors:  Xuejiao Tian; Saiyang Zhang; Hong-Min Liu; Yan-Bing Zhang; Christopher A Blair; Dan Mercola; Paolo Sassone-Corsi; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

4.  Critical Function of PRDM2 in the Neoplastic Growth of Testicular Germ Cell Tumors.

Authors:  Erika Di Zazzo; Carola Porcile; Silvia Bartollino; Bruno Moncharmont
Journal:  Biology (Basel)       Date:  2016-12-14

5.  Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.

Authors:  G Liu; A Bollig-Fischer; B Kreike; M J van de Vijver; J Abrams; S P Ethier; Z-Q Yang
Journal:  Oncogene       Date:  2009-09-28       Impact factor: 9.867

6.  The predictive value of PRDM2 in solid tumor: a systematic review and meta-analysis.

Authors:  Caroline Tanadi; Alfredo Bambang; Indra Putra Wendi; Veronika M Sidharta; Linawati Hananta; Anton Sumarpo
Journal:  PeerJ       Date:  2020-04-29       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.